TABLE 1.
KEGG pathways significantly enriched with genes with altered expression in COVID19 patients and schizophrenia patients treated with aripiprazole.
| Pathway ID | Source | Pathway name | Observed % | Expected % | p value Fisher | No. of genes per pathway | Gene symbol |
|---|---|---|---|---|---|---|---|
| hsa05321 | KEGG | Inflammatory bowel disease (IBD) | 8.16 | 0.57 | 0.00021 | 4 | GATA3 HLA-DQB1 IL18 STAT4 |
| hsa04658 | KEGG | Th1 and Th2 cell differentiation | 8.16 | 0.82 | 0.00079 | 4 | GATA3 HLA-DQB1 NFATC2 STAT4 |
| hsa04380 | KEGG | Osteoclast differentiation | 8.16 | 1.17 | 0.00281 | 4 | BTK NFATC2 SYK LILRB4 |
| hsa04664 | KEGG | Fc epsilon RI signaling pathway | 6.12 | 0.62 | 0.00382 | 3 | BTK PLA2G4A SYK |
| hsa04662 | KEGG | B cell receptor signaling pathway | 6.12 | 0.65 | 0.00430 | 3 | BTK NFATC2 SYK |
| hsa05164 | KEGG | Influenza A | 8.16 | 1.50 | 0.00653 | 4 | HLA-DQB1 HLA-DQB1 IL18 NLRP3 |
| hsa04064 | KEGG | NF-kappa B signaling pathway | 6.12 | 0.84 | 0.00867 | 3 | BTK LTA SYK |
| hsa04659 | KEGG | Th17 cell differentiation | 6.12 | 0.95 | 0.01202 | 3 | GATA3 HLA-DQB1 NFATC2 |
| hsa04611 | KEGG | Platelet activation | 6.12 | 1.09 | 0.01712 | 3 | BTK PLA2G4A SYK |
| hsa05166 | KEGG | HTLV-I infection | 8.16 | 2.33 | 0.02787 | 4 | FZD2 HLA-DQB1 LTA NFATC2 |
| hsa05152 | KEGG | Tuberculosis | 6.12 | 1.53 | 0.03986 | 3 | HLA-DQB1 IL18 SYK |